Obesity Market Set for Take-Off
- PDF / 2,145,791 Bytes
- 6 Pages / 612.28 x 790.87 pts Page_size
- 96 Downloads / 166 Views
Obesity Market Set for Take-Off Acomplia is Leading the Way ( Executive Summaty )
O
besity is now regarded as a chronic disease and is reaching epidemic proportions in industrialized and developing countries alike. At present in the US, nearly 65% of adults are considered overweight or obese. On a global scale, World Health Organization estimates suggested there were 200 million obese adults worldwide in 1995, jumping to over 300 million by 2000. 'Mlile the obesity market is potentially huge, antiobesity drugs have historically failed to sell. particularly in the US. The key factor behind this muted market response is likely to be the difficulty in securing reimbursement from the healthcare insurers. One way for pharmaceutical companies to tackle this issue is to shift this drug class away from the 'lifestyle' category and to 'medicalize' obesity. Lehman Brothers is forecasting the new antiobesity agents to erode generic phenterrnine market share from 2006 onwards, pushing the global market value from SUS330 million in 2003 to around $US2 billion in 2010. The pipeline for antiobesity drugs is very active, 'Mth many companies on the verge of capitalizing on the increasing 'medicalization' of obesity begun by Roche and Abbott. Much of the development is taking place in the US. AccmpIia '" lrimonabant) is a.rrentIy in phase III deYeIopment'Mth SanofiSyntheIabo. It is the first in a new dass of drugs called selective cannabinoid CB I receptor antagonists (CB I bIodcersI and will be the next drug to enter the weight_ market The encJocannabinoid $YSfem is believed to play a role in maintaining energy balance ttvough the regulation of food intake and energy expenditure, although the exact mechanism of the pathway is not yet fully understood. By seIectiYeIy blocking the CB I receptor, it is hoped that AccmpIia wi help namaIize the body's energy e
Data Loading...
